
Chimpanzees can ‘catch' yawns even from robots
Yawning is known to be associated with attention changes, regulating body temperature, and as a transition between rest and arousal.
Contagious yawning is a strange behaviour in which an animal yawns after seeing another individual exhibit the same behaviour.
This contagious aspect of the behaviour has been linked to some elements of social interaction, like empathy and imitation.
Until now, contagious yawning has been observed in mammals and some fish, but its evolutionary origins are still unknown.
It emerges gradually in humans, chimpanzees, and dogs, becoming prominent at around four years in humans, five years in chimpanzees, and at about seven months in dogs, scientists say.
The new study, published on Thursday in the journal Nature, found that chimpanzees will both yawn and lie down in response to yawns made by an android robot.
The findings suggest that observing another individual yawn may act as a cue in chimps to rest rather than triggering an automatic response.
In the study, scientists used an android head that could simulate facial expressions to test the responses of 14 adult chimps aged between 10 and 33 years.
The android head contained 33 rotational motors which functioned as muscles to generate its facial expressions, including yawns, with each expression lasting 10 seconds.
Chimps in the study were each exposed to four 15-minute sessions of the android demonstrating yawning, gaping, and neutral facial expressions.
Scientists recorded these sessions on camera, and each chimpanzee was scored for their responsiveness, along with the amount of time they spent lying down.
Eight of the 14 chimpanzees were found to yawn in response to the android's 'yawn' expression.
'The results showed that adult chimpanzees exhibited across-agent yawn contagion, with a graded response: the highest contagion occurred when the android displayed a fully wide-open mouth, a reduced response when the mouth was partially opened, and no contagion when the android's mouth was closed,' they wrote.
Eight chimps also lay down in response, and some gathered bedding before lying down.
'Chimpanzees engaged in behaviours associated with drowsiness, such as gathering bedding materials, constructing nests, and lying down, while observing the android yawning,' scientists wrote.
These findings seem to show contagious yawning due to an inanimate model for the first time, according to researchers.
The results shed further light on primates' susceptibility to contagiously induced behaviours, scientists say, adding, however, that the exact biological mechanisms surrounding it remain unclear.
They hope future research can reveal whether other actions performed by robots are contagious to animals.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medical News Today
an hour ago
- Medical News Today
Does semaglutide really contribute to vision loss?
As the popularity of GLP-1 medications used for weight loss continues to increase, more research is being done to further examine potential side effects of these medications. One such side effect is possible eye issues and vision loss, for which there is currently a great deal of conflicting studies link GLP-1 use to an increased risk for ocular diseases such as nonarteritic anterior ischemic optic neuropathy (NAION), diabetic retinopathy, papillitis, and optic nerve disorders. A new study reports that using semaglutide is not associated with an increased risk for eye disorders or diabetic this new study found a connection between semaglutide use and NAION, researchers say that the current evidence is insufficient to establish a definitive connection between the two. As the popularity of glucagon-like peptide-1 receptor agonists (GLP-1) used for the treatment of diabetes and in some cases for weight loss continues to increase, more research is being done to further examine potential side effects of these medications. One such side effect is possible eye issues and vision loss, for which there is currently a great deal of conflicting information. For example, a study published in July 2024 found participants taking semaglutide — the active ingredient found in Ozempic and Wegovy — were potentially at a higher risk of developing nonarteritic anterior ischemic optic neuropathy (NAION). Research published in February 2025 linked use of both semaglutide and tirzepatide — the active ingredient in Zepbound and Mounjaro — to not only an increased risk for NAION, but also papillitis and paracentral acute middle maculopathy. More recently, two studies published earlier this month showed similar findings. One study discovered that those taking semaglutide or tirzepatide may be at a higher risk of developing NAION than previously reported, as well as an increased risk of developing other optic nerve while the second study did not find a correlation between GLP-1 use and an increased risk for NAION, it did report a possible heightened chance for diabetic an additional study, also published this month in the journal JAMA Ophthalmology, reports that semaglutide is not associated with an increased risk for eye disorders or diabetic while the study did find a connection between semaglutide use and NAION, researchers say that the current evidence is insufficient to establish a definitive connection between the two. Why is there so much conflicting information on GLP-1s and eye issues? For those currently using or considering using GLP-1 medications, it can be confusing and frustrating to have multiple studies with differing — and sometimes conflicting — findings around a potential risk to eye health and vision. 'We've seen a couple of studies now that are coming out, especially because of how regularly these medications are being used now,' Benjamin Bert, MD, a board-certified ophthalmologist at MemorialCare Orange Coast Medical Center in Fountain Valley, CA — who was not involved in any of these studies — told Medical News Today.'And as expected, when we're talking about rare diseases, especially things like NAION, we do see some variability in the results that have been coming out,' added Bert.'Most of the research that's been published, including one of these two recent studies, does continue to support the idea that there is an increased risk of NAION occurring in patients that are taking these GLP-1 medications,' he continued.'It really just tells me that it's important, again, to go over all the risks and benefits with the patients of these different medications, and just let them know, hey, this is something new, we're still finding out about it, but there have been these reports of increasing the incidence,' Bert told us. 'We are seeing so many patients utilizing these drugs [that] we will see other complications during patient use that some would attribute to side effects of the medication,' David I. Geffen, OD, FAAO, director of optometric and refractive services at the Gordon Schanzlin New Vision Institute in La Jolla, CA, who was not involved in the research, explained to MNT. 'At this time early research in general shows the plus side of these medications outweighs some potential side effects.'Semaglutide not associated with diabetic retinopathy or eye disordersIn this most recent study, researchers conducted a systematic review of 78 clinical trials involving semaglutide use and ocular issues — including NAION, diabetic retinopathy, and eye disorders — encompassing more than 73,000 study participants. 'The risk of diabetic retinopathy came with the results of the SUSTAIN 6 trial, the first that compared the effect of semaglutide in cardiovascular outcomes in subjects with type 2 diabetes,' Fernando Gerchman, MD, PhD, professor of medicine in the Division of Endocrinology and Metabolism at the Hospital de Clínicas de Porto Alegre in Brazil and senior author of this study, told MNT. 'Observational data demonstrated a possible association between semaglutide and NAION,' Gerchman continued. 'This was replicated for others, but not in all studies published that look at this. We had the unique opportunity to meta-analyze with data derived from clinical trials. Our results confirmed these findings. However, there is some imprecision in our analyses and our findings need to be replicated.' Upon analysis, researchers found that semaglutide use was not associated with an increased risk for diabetic retinopathy or eye disorders. And although they did find a correlation between semaglutide use and NAION, scientists believe the evidence currently available is not enough to establish a definitive conclusion and more studies are needed.'These findings reassure [those] who prescribe semaglutide about the safety of doing that in diabetes and obesity,' Gerchman said. 'The risk of NAION needs to be taken into account and may help to decide about a more conservative approach in the definition of beginning semaglutide for those subjects without a clear indication for that.'Do I need to worry about my eyes when taking Ozempic? When looking at the results of these studies, Bert said it's important to note that when looking at the increases of percentages, it demonstrates that it is still very, very rare for a condition like NAION to occur.'[This study] reported in the control population that it was about 0.02% of the patients (with NAION), and in the treated group, the ones that were taking the GLP-1 medications, it went up to 0.04%,' he explained. 'So you could kind of sensationalize it and say, look, it doubled the risk for the patients to take the medication. But again, 0.02 to 0.04 is such a small amount that the overall risk is still very low.' Geffen commented that it is hard to tell a patient not to take GLP-1 medications unless they are already at high risk for NAION.'I feel the benefits for overall health make it a risk for the average person to take,' he continued. 'We need better studies developed for all the potential side effects of GLP-1 medications, not just eye related ones. So far these meds seem a godsend for many individuals.' For those considering starting GLP-1 medications, Bert advised talking to their physician and endocrinologist, and make sure to have an annual eye exam. 'It would be beneficial to have a baseline exam before you start the medication,' he explained. 'And then if you are high risk, of course, have another exam done shortly after starting just to make sure that you're not one of the people that fall into one of those categories where there can be worsening of the disease.' 'I think it's most important that these types of research projects continue to be done, and the benefit of having our electronic medical record systems, and we see in other countries that have kind of universal systems, you can do these very large population-based statistical analyses. And I think that needs to be continued as we progress into using these medications for longer periods of time, to ensure that we know the entirety of the risks and the benefits of them. So I would like to just continue to see this research being done and all these details flushed out.' – Benjamin Bert, MD


BreakingNews.ie
an hour ago
- BreakingNews.ie
Nasa's Webb telescope finds a new tiny moon around Uranus
The Webb Space Telescope has spotted a new tiny moon orbiting Uranus. The new member of the lunar gang, announced on Tuesday by Nasa, appears to be just six miles wide. Advertisement It was spotted by the telescope's near-infrared camera during observations in February. We're not sitting on this one, Uranus has another Moon! Webb discovered an unknown moon orbiting the planet, expanding its known satellite family to 29. — NASA Webb Telescope (@NASAWebb) August 19, 2025 Scientists think it hid for so long — even eluding the Voyager 2 spacecraft during its flyby about 40 years ago — because of its faintness and small size. Uranus has 28 known moons that are named after characters from Shakespeare and Alexander Pope. About half are smaller and orbit the planet at closer range. Advertisement This newest addition, still nameless, ups the planet's total moon count to 29.


The Independent
3 hours ago
- The Independent
How testing plane toilet waste could save lives
A study has found that testing aircraft toilet waste can help monitor the global spread of drug-resistant superbugs, often referred to as the 'silent pandemic'. Scientists analysed lavatory wastewater from 44 international flights arriving in Australia, detecting nine high-priority pathogens and superbugs. An antibiotic-resistance gene, not previously found in Australia's urban wastewater, was detected on 17 flights, suggesting its likely entry into the country through international air travel. Flights originating from Asia, particularly India, showed higher concentrations of antibiotic resistance genes compared to those from Europe and the UK. This research indicates that aircraft wastewater monitoring could serve as a valuable early-warning system for emerging superbug threats, complementing existing public health surveillance.